Arrhythmias & electrophysiology
Economic and Health Value of Delaying Atrial Fibrillation Progression Using Radiofrequency Catheter Ablation
Main finding · Net monetary benefit per patientResult — go to the resultMean net monetary benefit 8516 $ CI 148-16 681Authors' conclusion
RFCA is a dominant (less costly and more effective) treatment strategy for patients with AF, especially those with early AF for whom RFCA could delay progression to advanced AF.
Study context
- Population
- Hypothetical sample of patients with paroxysmal atrial fibrillation (AF)hypothetical sample
- Comparison
- Radiofrequency catheter ablation (RFCA) vs antiarrhythmic drug treatment
- Outcome
- Net monetary benefit per patient (discounted costs and QALYs)
- Follow-up
- Lifetime
Methodological detailsindividual-level state-transition model, hypothetical sample, payer's perspective, lifetime horizon, Lifetime risk of progression from paroxysmal to persistent AF informed by ATTEST data, Incremental effect of RFCA on progression modelled over 5 years
- Individual-level state-transition model
- Hypothetical sample
- Payer's perspective
- Lifetime horizon
- Lifetime risk of progression from paroxysmal to persistent AF informed by ATTEST data
- Incremental effect of RFCA on progression modelled over 5 years
Main finding
Net monetary benefit per patient
Mean net monetary benefit
8516 $
CI 148-16 681
As reported in the abstract
Further findings
| Outcome | Mean increase (QALYs) (95% CI) | |
|---|---|---|
| QALYs | 0.084 (0.0–0.17) | |
| −0.100.10.2Difference, QALYs (linear scale) |
| Outcome | Mean reduction ($) (95% CI) |
|---|---|
| Per-patient costs | 73 (-$2700 to $2200) |
CV-related health care encounters
- Mean number decreased with RFCA
- 24%
Original publication
Economic and Health Value of Delaying Atrial Fibrillation Progression Using Radiofrequency Catheter Ablation. Circ Arrhythm Electrophysiol. Published 9 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →